

## Special Issue

# 10th Anniversary of Biomedicines—Ophthalmology Disorders

### Message from the Guest Editors

This Special Issue aims to publish a Special Issue entitled “10th Anniversary of Biomedicines— Gene Therapy in Ophthalmology Disorders”. More than 200 million people worldwide are suffering from severe vision loss. For about 30% of patients suffering from neurodegenerative diseases, treatment options are limited. This includes inherited and frequent noncommunicable diseases such as age-related macular degeneration (AMD ) or glaucoma. Gene therapy opens up new avenues in the treatment of these disorders. The eye is particularly interesting for gene therapy due to its accessibility, small size and immune privilege, however, the high complexity of the organ, especially the neuroretina, is a challenge for the development of efficient approaches. Nevertheless, multiple studies are ongoing to analyze approaches to treating monogenetic inherited diseases, such as retinitis pigmentosa, and complex diseases such as AMD, encompassing viral and nonviral treatments, ex and in vivo approaches. We invite the submission of both original articles that report preclinical and clinical studies and reviews, in order to provide an overview on the current state of the art.

### Guest Editors

Prof. Dr. Gabriele Thumann

1. Department of Ophthalmology, University Hospitals of Geneva, Geneva, Switzerland
2. Experimental Ophthalmology, University of Geneva, Geneva, Switzerland

Dr. Martina Kropp

1. Department of Ophthalmology, University Hospitals of Geneva, Geneva, Switzerland
2. Experimental Ophthalmology, University of Geneva, Geneva, Switzerland

### Deadline for manuscript submissions

closed (31 December 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/si/110655](https://mdpi.com/si/110655)

*Biomedicines*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 5.2  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).